News

Patient Assistance Programs Fill Vital Need for Those With Rare Diseases


 

References

Some health care analysts have criticized patient assistance programs (PAPs) as a cause of growth in prescription drug spending and overall health care costs. The National Organization for Rare Disorders (NORD) has published a position statement to address this issue and explain the essential function of charitable assistance programs for patients with rare diseases. Specifically, NORD’s position is that PAPs do not inflate the cost of treatment and that they ensure patient access to lifesaving therapies. Read NORD’s position paper.

Recommended Reading

Free Summer Camp For Families of Children With Rare Diseases
MDedge Endocrinology
NORD Speaks on Behalf of Continued Funding for NIH Undiagnosed Diseases Network
MDedge Endocrinology
NIH and FDA Release a Draft Clinical Trial Protocol Template for Public Discussion
MDedge Endocrinology
News From NORD Round-Up: April 2016
MDedge Endocrinology
TSH antibody levels predict Graves relapse after thionamides
MDedge Endocrinology